Purpose To concisely present recommendations and guidelines for venous thromboembolism (VTE) treatment and prevention for common subgroups of surgical patients as a comprehensive reference for clinical surgical practice.
Introduction:
Venous thromboembolism (VTE), which includes deep venous thrombosis (DVT) and pulmonary embolism (PE) occurs in up to 25% of those hospitalized, a population vulnerable to the elements of Virchow's Triad (stasis, hypercoagulability, and endothelial injury). 1 Although guidelines are in place to mitigate this, any ambiguity can lead to significant morbidity and mortality, particularly because 50% of all DVTs are asymptomatic, with approximately 30% having additional complications. 2 In some instances, a DVT is self-limited, and resolves when the instigating disease process has been treated. However, in more than 1/3 of patients it can lead to a PE, which can in turn precipitate death in up to 34% of patients. 3 If the embolus in the lung fails to completely dissolve, chronic pulmonary hypertension may eventually occur, causing chronic shortness of breath and varying degrees of heart failure.
The Surgeon General's First Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism came in 2008 and estimated 350,000 to 600,000 Americans each year are afflicted by thromboembolic disease, with at least 100,000 attributable deaths. 3 This is estimated to be the number one cause of preventable death in hospitalized patients. To combat this risk, the Surgical Care Improvement Project encouraged chemoprophylaxis administration within 24 hours of an operation. The Joint Commission also supports this ideology, recommending all surgical patients receive anticoagulation, which is congruent with measures adopted by the Centers for Medicare and Medicaid Services in 2009. 4 Despite these initiatives and mandates, VTE prophylaxis is underutilized in the United States. A 2009 analysis revealed that only 34% of high-risk patients receive appropriate prophylaxis. 5 Further studies revealed that only 58.5% of surgical patients received VTE prophylaxis. 4 The reasons delineated for recommendation nonadherence included fear of anticoagulant-associated bleeding, lack of VTE awareness, generalization of recommendations rather than patient subset specific guidelines, and difficulty of reinforcing protocols because of effort involved in individual risk assessment. This is particularly significant, because these patients face complex medical issues that challenge the way in which they live their lives. Symptomatic patients with a PE have a higher risk of recurrent VTE than those with symptomatic VTE alone. There is a higher recurrence rate of VTE in men than women (20% vs 6%, relative risk 3.6). 2,6 Chronic venous insufficiency (CVI) may develop after DVT. CVI is also known as post-thrombotic syndrome (PTS), which and future risk of VTE progression versus bleeding. Low-molecular-weight heparin is the preferred anticoagulant for initial treatment of VTE. The tenth edition of ACCP VTE guidelines provides comprehensive management recommendations.
can occur months to years following a thrombotic event in up to 30% of patients. CVI results from a thrombus injuring or destroying one or more of the venous valves in deep veins of the leg, resulting in leg pain and edema with prolonged standing, accompanied by mild to extensive varicose veins, skin breakdown, ulceration, and eventually skin pigmentation changes.
These patients may also develop chronic venous stasis ulcers, which can be complex to manage. [6] [7] [8] The need for lifestyle-altering vigilance is often required to avoid and manage the potential impact of other risk factors, ranging from routine activity such as lengthy travel, to significant events like surgery and trauma. Table  2 summarizes ACCP recommendations for both initial and longterm treatment of patients with varying contributing factors. Patients with a malignant process should undergo anticoagulation with low molecular weight heparin (LMWH), as it has been shown to be more effective when compared to Vitamin K Antagonists (VKA) in this population, including against recurrent thromboembolic processes. It is also easier to titrate doses, and a non-oral medication may be better tolerated in patients who may be prone to nausea and vomiting. Those without a malignant process can typically tolerate an oral VKA well, barring other factors detailed here.
CHOICE OF ANTICOAGULANT
In those who cannot tolerate parenteral medications, rivaroxaban and apixaban were recommended. This is largely because these medications can be dosed without the requirement of a parenteral bridging medication.
Organ damage should also play a role in anticoagulant decision making. In patients with hepatic insufficiency, LMWH is preferred in the setting of elevated international normalized ratio (INR). Novel oral anticoagulants (NOAC) are contraindicated in this population. VKA can be challenging to dose as the INR may not be truly reflective of anticoagulation. In contrast, those with renal insufficiency should undergo anticoagulation with VKA, as other anticoagulants can yield further renal damage.
Dabigatran has been shown to have more frequent instances of coronary artery events, and should be avoided in these patients. It has also been associated with dyspepsia, which should be a consideration for patient adherence. Dabigatran, rivaroxaban, and edoxaban have also been implicated in a higher number of instances of gastrointestinal bleeding than VKAs.
LMWH is the agent of preference for pregnant patients, as other agents have the potential to cross the placenta. Additionally, LMWH is the agent of choice for those patients with epidurals in place. LMWH should be held for 24 hours after the epidural has started, and discontinued 10-12 hours prior to catheter removal. Chemoprophylaxis can be re-initiated 24 hours after catheter removal.
Of course, other factors such as cost, route of administration, insurance coverage, and drug level monitoring should all be assessed when choosing the appropriate anticoagulant agent for a specific patient.
CAPRINI SCORE AND INDIVIDUALIZED RISK ASSESSMENT
A standardized approach to addressing DVT prophylaxis is by assessing a patient's Caprini Score. This metric incorporates physical symptoms, history, and attributes as well as comorbid factors to align a patient into one of four risk category stratifications guiding anticoagulant use. 12-14 A score of 0 equates to Very Low risk, while 1-2 correlates to Low risk. Caprini Scores greater than 2 are deemed moderate risk, and scores greater than 5 are high risk for VTE. 14 The Caprini score uses risk factors for VTE to assign points, resulting in a score with which the surgeon can weigh the risk of bleeding against the risk of VTE to determine what prophylaxis is appropriate for an individual patient. There is a direct correlation between an increased risk score and the development of clinically relevant VTE over a wide variety of surgical subspecialties. 13 The Caprini score "avoids blanket prophylaxis with anticoagulants since those with low scores have a risk of thrombosis that is lower than the bleeding risks with anticoagulation." 6 In a practical translation, a Caprini score greater than 8 increases the risk of VTE about 20-fold, whereas scores of 7 to 8 are at a 5-to 10-fold increase when compared with low-risk patients across surgical subspecialties. [15] [16] Table 3 outlines the factors used to tabulate the Caprini Score, as well as the protocol recommended for each risk grouping.
Those who fall into the Very Low category simply require mechanical prophylaxis via early and frequent ambulation, while those in the Low group should have more substantial mechanical prophylaxis in the form of sequential compression devices (SCDs). At the Moderate level, patients should have chemoprophylaxis with or without the addition of SCDs. Those who are found to be High risk are recommended to have both chemoprophylaxis and SCDs.
ACCP TENTH EDITION RECOMMENDATIONS AND GUIDELINE UPDATES
Two significant principles in the management of VTE are avoiding clot extension and recurrence of DVT in order to reduce the risk of PE and the occurrence of PTS. The current school of thought recommends treatment with NOACs rather than VKA in patients whose VTE disease process is not present in the setting of malignancy. For those with VTE in the setting of malignancy, LMWH remains this anticoagulant of choice. However, as previously detailed, there may be extenuating factors to consider on a caseby-case basis that makes one agent preferable over another.
Additionally, the use of graduated compression stockings is no longer regularly suggested for PTS prevention, and IVC filters should not be placed for those patients who can tolerate anticoagulation. Those who have an unprovoked PE should be considered for anticoagulation without endpoint, and thrombolytics should be avoided in those with PE who are anticoagulated in the setting of normotension without acute decompensation. All ACCP tenth edition updates are Grade 1 or 2 guidelines, however, none are based on Grade A evidence. These updates are summarized in Table 4 . 17 Copyright 2019 KEI Journals. All Rights Reserved http://journals.ke-i.org/index.php/mra 
Acute PE in setting of normotension  no systemically administered thrombolytics 1B Acute PE with deterioration status post anticoagulant administration in setting of normotension with low bleeding risk  systemically administered thrombolytics > no thrombolytics 2C

Catheter-Based Thrombus Removal for the Initial Treatment of PE Acute PE treated with thrombolytics  systemic thrombolytic therapy via peripheral vein > CDT 2C Acute PE in setting of hypotension with high bleeding risk, failed systemic thrombolysis, or shock with threat of imminent mortality prior to systemic thrombolysis becoming therapeutic (within hours) and appropriate expertise/resources available  catheter-assisted thrombus removal > no catheter-assisted thrombus removal
2C
Pulmonary Thromboendarterectomy for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Select chronic thromboembolic pulmonary hypertension under care of thromboendarterectomy team  pulmonary thromboendarterectomy > no pulmonary thromboendarterectomy 2C
Thrombolytic Therapy in Patients with Upper Extremity DVT Acute upper extremity DVT involving axillary or more proximal veins  anticoagulant therapy alone > thrombolysis 2C
Acute upper extremity DVT status post thrombolysis  same intensity and duration of anticoagulation treatment as those who do not undergo thrombolysis 1B
Management of Recurrent VTE on Anticoagulant Therapy Recurrent VTE on therapeutic VKA treatment or compliant dabigatran, rivaroxaban, apixaban, or edoxaban use  at least temporary switch to LMWH 2C
Recurrent VTE on long-term compliant LMWH  increase LMWH dose ~ ¼ -⅓ 2C
Summary of ACCP CHEST 10 guideline recommendations
INFERIOR VENA CAVA FILTERS
VENOUS THROMBOEMBOLISM PREVENTION IN SPECIFIC PATIENT POPULATIONS General
The grouping of general surgery procedures is largely inclusive of abdomino-pelvic Copyright 2019 KEI Journals. All Rights Reserved http://journals.ke-i.org/index.php/mra operations. These procedures tend to range form low to high Caprini score, with ~ 1% baseline bleeding risk. The baseline thrombotic risk increases in the setting of malignancy to 3.7%, which those without a cancerous disease process have a baseline thrombotic risk of approximately 0.5 -1.6%. Factors that alter the baseline risk in this patient population include age, malignancy, type of procedure, and length of operative time. Data analysis of patients undergoing colon resection showed no significant difference for bleeding events nor thrombotic events when comparing patients who received pre-and postoperative chemoprophylaxis with only postoperative chemoprophylaxis. This suggests no clear recommendation for the timing of chemoprophylaxis in those such cases. 19 The information presented to follow reflects the most recent version of the ACCP's guidelines on VTE prevention for specific surgical specialties. It is intended as a concise summary of the rationale and final recommendations taking into account the unique characteristics of each patient population. Low -High 0.5 -1.6%; up to 3.7% with cancer 1%
Bariatric
Low -High 1.9 -5.4%; less extensive procedures as low as 0.5% <1%
Noncardiac Vascular
Low -High
Open abdomen: up to 10% Peripheral artery surgery: 1.8 -9%
Venous ablation: < 1% Lower extremity amputation: 2 -15%; higher for above knee amputation 0.3 -1.8%
Plastic / Reconstructive
Low-High 0.5 -1.8% 0.5 -1.8%
Cardiac
Moderate -High Up to 1% 5%
Noncardiac Thoracic
Moderate -High 0.18 -7.4%; pneumonectomy, esophagectomy highest 1%
Neurosurgery
Moderate -High
Pooled: 16 -29%; highest for craniotomy Spinal: 0 -15%; benign and cervical spine less Pooled: 1 -1.5%
Spinal: < 0.5%
Major Trauma
Moderate -High
Most severe injuries: 58% No prophylaxis: 8.7% Mechanical prophylaxis only: 3.7%
-4.7%
Caprini categorization, VTE risk, and bleeding risk stratified by type of surgery
Minimally Invasive Surgery
In 2017, the Society of American Gastrointestinal Endoscopic Surgeons published a statement in support of the updated VTE guidelines from the ACCP rather than updating their previously published VTE prophylaxis recommendations for various procedures. This endorsement takes into consideration the use of the Caprini model for VTE risk stratification, as well as the general recognition of the ACCP guidelines as thorough, comprehensive, and easy to implement. 20
Bariatric
By nature, bariatric patients are at higher risk for VTE secondary to obesity and associated comorbidities. The Caprini classification for these procedures tends to fall in the low to high range, with 1.9 to 5.4% risk of thrombosis; less extensive procedures have risk as low as 0.5%. The risk of bleeding in these cases is typically <1%. The American Society of Bariatric and Metabolic Surgeons recommends mechanical prophylaxis and early ambulation for this subgroup of patients, and leaves the decision for chemoprophylaxis to each independent surgeon. If chemoprophylaxis is ordered, there is some evidence for LMWH as a preferred agent. 21 A 2013 survey of practice patterns among 385 bariatric surgeons revealed the majority agreed on what qualifies a patient as high risk and use VTE chemoprophylaxis preoperatively. VTE screening and duration of therapy, however, varied widely among practitioners. Most of the surgeons surveyed routinely performed bariatric surgery laparoscopically (98.7%). 22 Risk factors thought to qualify a patient as high risk for VTE included history of DVT, known hypercoagulable status, severe immobility, body mass index exceeding 55 kg/ m2, and PaO2 less than 60 mm Hg. More than half of the surgeons routinely performed preoperative DVT screening (56%), either by clinical examination alone (33.1%) or routine ultrasound (20.9%). Preoperative VTE prophylaxis was used by 92.4% of respondents, with 48.0% using unfractionated heparin, 33.4% using enoxaparin sodium (Lovenox), 2.6% using fondaparinux, and 8.3% using another agent. Retrievable IVC filters have also been used in the past with this patient population, and 28.1% continue to routinely use them preoperatively. 22 Sequential compression devices were used by most of the respondents, both intraoperatively and postoperatively (96.3% and 91.6%, respectively). Postoperative chemical prophylaxis was also used routinely (97%), starting on postoperative day 0 in most (70%). Lovenox was the most commonly used agent (49.5%), followed by heparin (33%), other agents (9.1%), and fondaparinux (5.4%). Chemical prophylaxis was discontinued at discharge in most cases (48.5%). If continued after discharge (as with 43.8% of respondents), the most common duration of therapy was 2 to 4 weeks (40.1%) with Lovenox (39.7%). If a retrievable IVC filter was used, it was most commonly removed 30 to 90 days postoperatively (55.2%). 35 The wide range of practice patterns among bariatric surgeons reflects the need for validated studies regarding this subset of patients.
Vascular
Vascular procedures have a variable risk of generating thrombotic disease processes; a major open abdominal vascular intervention can carry a thrombogenic risk of up to 10%, whereas a lower extremity amputation has a risk of 2 to 15% (higher in above the knee amputations), peripheral arterial procedures 1.8 to 9%, venous ablation < 1%. In general, vascular operations have a bleeding Copyright 2019 KEI Journals. All Rights Reserved http://journals.ke-i.org/index.php/mra risk of 0.3 to 1.8%. These interventions typically fall in the low to high Caprini category. Interestingly, it has been shown that while endovascular aneurysm repair has a lower incidence of VTE when compared to open interventions, however DVT incidence status post endovascular approach was found to be 5.3% regardless of chemoprophylaxis. 23 When considering chemoprophylaxis for amputations, it is important to consider the level at which the limb will be severed, as the amount of tissue loss has varying functionality and mobility that impacts its associated recovery process. This can lend to the decision for preoperative chemoprophylaxis. Those who do develop VTE status post amputation have higher morbidity and mortality, as well as a longer rehabilitation course. [24] [25] Neurosurgery VTE risk for patients undergoing neurosurgery is higher than the general population, falling in the Moderate to High Caprini category. In the unstratified population of neurosurgery patients, the risk of VTE is 16% to 29%, with craniotomy being among the highest risk procedures. These patients have a bleeding risk of 1% to 1.5%. When stratified by injury type, those who sustain spinal cord injuries have a risk for developing a VTE of 0% to 15%, with benign processes at less risk. The risk of bleeding for these patients is <0.5%. The increased risk for VTE exists for at least a year status post inciting injury, the highest risk being within the first three months. [26] [27] [28] VTE chemoprophylaxis can certainly be justified in this acute phase after injury, if no contraindication to administration exists. If bleeding risk or other contraindications do prevent pharmaceutical prophylaxis, mechanical prophylaxis is reasonable. [29] [30] [31] For those undergoing elective neurosurgery, the use of postoperative VTE chemoprophylaxis is supported. 32 
Major Trauma
The risk of DVT in trauma patients can vary from 5% to 63%, and is influenced by risk factors, prophylaxis modality, and methods of detection. [33] [34] Coagulopathy in trauma patients is multifactorial, with contributions from elements such as the consumption of clotting factors, acidosis, hypothermia, dilutional changes secondary to resuscitation, blood product administration, immobility, and shock, as well as the systemic activation of anticoagulant and fibrinolytic pathways associated with shock. 35 Greenfield and colleagues developed a validated risk assessment profile (RAP) to identify the factors associated with an increased incidence of DVT. [36] [37] In this study, patients with an RAP score of 5 or more were 3 times more likely to develop VTE than patients with an RAP score less than 5. 
